Smith & Nephew, the British multinational medical equipment manufacturer, saw its share price increase by approximately 5% last week. The increase in share price was triggered as a result of Smith & Nephew receiving Food and Drug Administration ("FDA") clearance for its AETOS Shoulder System. This is the latest solution in Smith & Nephew’s expanding Upper Extremity portfolio and is designed to maximise stability, preserve bone and maintain patient anatomy. The company also noted that total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025... Stocks featured: Smith & Nephew, Glencore and 888 Holdings To find out more about the investment management services offered by Walker Crips, please visit our website: https://www.walkercrips.co.uk/ This podcast is intended to be Walker Crips Investment Management’s own commentary on markets. It is not investment research and should not be construed as an offer or solicitation to buy, sell or trade in any of the investments, sectors or asset classes mentioned. The value of any investment and the income arising from it is not guaranteed and can fall as well as rise, so that you may not get back the amount you originally invested. Past performance is not a reliable indicator of future results. Movements in exchange rates can have an adverse effect on the value, price or income of any non-sterling denominated investment. Nothing in this podcast constitutes advice to undertake a transaction, and if you require professional advice you should contact your financial adviser or your usual contact at Walker Crips. Walker Crips Investment Management Limited is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Hosted on Acast. See acast.com/privacy for more information.